IN 002
Alternative Names: IN-002Latest Information Update: 22 Mar 2024
At a glance
- Originator Inhalon Biopharma
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 20 Mar 2024 Inhalon Biopharma plans clinical trials in Respiratory syncytial virus infections (Inhalation)
- 01 Jun 2021 IN 002 is available for licensing as of 01 Jun 2021. https://www.inhalon.com/contact
- 26 May 2021 Inhalon Biopharma in-licenses muco-trapping technology from John Hopkins University and University of North Carolina at Chapel Hill before May 2021